Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.


PURPOSE Estramustine and etoposide (VP-16) have been demonstrated to inhibit the growth of prostate cancer cells in experimental models. This led us to evaluate the effectiveness of this combination in the treatment of patients with metastatic prostate carcinoma refractory to hormone therapy. PATIENTS AND METHODS Estramustine 15 mg/kg/d and VP-16 50 mg/m2… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.